Edesa Biotech, Inc. (EDSA) - Dilution Analysis

10-Q filing | 8.5M shares outstanding

10-K filing | 8.3M shares outstanding

10-Q filing | 7.0M shares outstanding

S-3 filing: This S-3 filing is for a shelf offering of common shares by selling shareholders.

10-Q filing | 6.9M shares outstanding

8-K filing: Edesa Biotech, Inc. entered into a Securities Purchase Agreement for a private placement of Preferred Shares and Common Shares, resulting in gross proceeds of approximately $15.0 million. ($15.0M proceeds)

10-K filing | 3.2M shares outstanding

10-Q filing | 3.2M shares outstanding

10-Q filing | 3.2M shares outstanding

10-Q filing | 3.2M shares outstanding

10-K filing | 2.4M shares outstanding

8-K filing: Stock split 1-for-7 | Outstanding: 20,866,772 → 3,072,482

10-Q filing | 20.9M shares outstanding

10-Q filing | 20.1M shares outstanding

10-Q filing | 19.4M shares outstanding

S-3 filing: The filing is an S-3 form regarding the offering of up to 5,382,667 common shares by selling shareholders, including shares issuable upon the exercise of Class A and Class B Warrants. The company will not receive any proceeds from the sale of shares by the selling shareholders but will receive proceeds from any cash exercise of the Warrants.

10-K filing | 16.7M shares outstanding

8-K filing: Edesa Biotech, Inc. closed an offering of 2,691,337 common shares along with warrants for gross proceeds of approximately $3.0 million on November 2, 2022. ($3.0M proceeds)

10-Q filing | 15.5M shares outstanding

S-3 filing: Edesa Biotech, Inc. is filing an S-3 to offer up to $150,000,000 in various securities including common shares, preferred shares, debt securities, warrants, subscription rights and units.

10-Q filing | 15.5M shares outstanding

S-1 filing: S-1 filing for resale of common shares issuable upon exercise of warrants.

8-K filing: Edesa Biotech, Inc. entered into a purchase agreement to sell and issue 1,540,000 common shares and pre-funded warrants to purchase up to 1,199,727 common shares at $3.65 and $3.6499 respectively, along with warrants to purchase up to 2,739,727 common shares in a concurrent private placement, for gross proceeds of approximately $10.0 million, with the offering expected to close on or about March 24, 2022.

8-K filing: Edesa Biotech, Inc. and RBC Capital Markets, LLC amended the Equity Distribution Agreement, with the Company having sold 487,228 common shares for $2,500,069 prior to March 4, 2022, and may offer and sell additional Common Shares up to $15.4 million. ($2.5M proceeds)

10-Q filing | 13.5M shares outstanding

10-K filing | 13.3M shares outstanding

10-Q filing | 13.3M shares outstanding

10-Q filing | 13.2M shares outstanding

8-K filing: Edesa Biotech, Inc. entered into an underwriting agreement with H.C. Wainwright & Co., LLC to sell 1,562,500 common shares at $6.40 per share in a firm commitment public offering, with an option for Wainwright to purchase an additional 234,375 shares. ($10.0M proceeds)

10-Q filing | 11.0M shares outstanding

10-K filing | 10.5M shares outstanding

10-Q filing | 8.9M shares outstanding

10-Q filing | 8.9M shares outstanding

S-1 filing: The company is issuing and selling 1,354,961 Common Shares in a registered direct offering and warrants to purchase Common Shares in a concurrent private placement.

10-Q filing | 8.9M shares outstanding